Eli Lilly and Company (NYSE:LLY) Shares Purchased by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 27.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 136,025 shares of the company's stock after acquiring an additional 28,985 shares during the quarter. Eli Lilly and Company makes up 1.0% of Teachers Retirement System of The State of Kentucky's portfolio, making the stock its 9th biggest holding. Teachers Retirement System of The State of Kentucky's holdings in Eli Lilly and Company were worth $112,345,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. WestEnd Advisors LLC raised its holdings in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the period. Citizens National Bank Trust Department increased its holdings in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter worth $40,000. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth $43,000. Finally, O Brien Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price target for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Finally, The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Stock Up 2.0%

Shares of Eli Lilly and Company stock traded up $14.96 during trading hours on Tuesday, reaching $777.14. 1,581,058 shares of the company were exchanged, compared to its average volume of 3,654,005. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock's fifty day moving average is $767.03 and its 200 day moving average is $800.17. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a market cap of $736.53 billion, a PE ratio of 63.13, a PEG ratio of 1.12 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the company posted $2.58 EPS. Eli Lilly and Company's quarterly revenue was up 45.2% on a year-over-year basis. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.